Your browser doesn't support javascript.
Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study.
Tomasiewicz, Krzysztof; Piekarska, Anna; Stempkowska-Rejek, Justyna; Serafinska, Sylwia; Gawkowska, Aleksandra; Parczewski, Milosz; Niscigorska-Olsen, Jolanta; Lapinski, Tadeusz W; Zarebska-Michaluk, Dorota; Kowalska, Justyna D; Horban, Andrzej; Flisiak, Robert.
  • Tomasiewicz K; Department of Infectious Diseases, Medical University of Lublin , Lublin, Poland.
  • Piekarska A; Department of Infectious Diseases and Hepatology, Medical University of Lodz , Lodz, Poland.
  • Stempkowska-Rejek J; Department of Infectious Diseases, Medical University of Lublin , Lublin, Poland.
  • Serafinska S; Department of Infectious Diseases and Hepatology, Wroclaw Medical University , Wroclaw, Poland.
  • Gawkowska A; Department of Infectious Diseases and Hepatology, Wroclaw Medical University , Wroclaw, Poland.
  • Parczewski M; Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University , Szczecin, Poland.
  • Niscigorska-Olsen J; Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University , Szczecin, Poland.
  • Lapinski TW; Department of Infectious Diseases and Hepatology, Medical University of Bialystok , Bialystok, Poland.
  • Zarebska-Michaluk D; Department of Infectious Diseases, Voivodeship Hospital and Jan Kochanowski University , Kielce, Poland.
  • Kowalska JD; Department of Adults' Infectious Diseases, Medical University of Warsaw , Warsaw, Poland.
  • Horban A; Department of Adults' Infectious Diseases, Medical University of Warsaw , Warsaw, Poland.
  • Flisiak R; Department of Infectious Diseases and Hepatology, Medical University of Bialystok , Bialystok, Poland.
Expert Rev Anti Infect Ther ; 19(1): 93-100, 2021 01.
Article in English | MEDLINE | ID: covidwho-1066154
ABSTRACT

BACKGROUND:

Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the inflammatory response and control the symptoms of severe coronavirus disease 2019 (COVID-19), but the evidence is scarce.

METHODS:

This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers.

RESULTS:

Twenty-eight patients were included (19 male), with a mean age of 61.7 ± 12.4 years. The mean time from symptom onset to the first tocilizumab dose was 10.5 ± 5.7 days. Clinical status improved within 24 hours in 11 (39%) patients, within one week in 23 (82%) patients, and within two weeks in 25 (89%); one (4%) patient showed no change and two (7%) patients died. Sixteen patients (57%) no longer needed oxygen therapy within a week (p < 0.001). The serum concentrations of C-reactive protein, procalcitonin, and fibrinogen decreased significantly (p ≤ 0.001). Lung changes improved in 21 (84%) patients within two weeks of treatment; 19 had minimal or no changes upon final examination.

CONCLUSIONS:

Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Expert Rev Anti Infect Ther Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 14787210.2020.1800453

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Expert Rev Anti Infect Ther Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 14787210.2020.1800453